18F-FDG PET/CT显像在治疗后宫颈癌评估中的价值

目的 探讨18F-FDG PET/CT对临床怀疑宫颈癌局部复发和(或)远处转移患者的诊断价值.方法 回顾性分析95例宫颈癌治疗后患者的18F-FDG PET/CT检查资料,采用视觉分析和半定量方法(SUVmax)分析病灶特点,最终诊断以活组织病理检查、诊断性治疗及影像学随访结果为准,采用Kappa一致性检验进行分析.结果 共有54例患者18 F-FDG PET/CT检查发现局部复发和(或)远处转移病灶,其中局部复发24例,远处转移30例;18F-FDG PET/CT诊断肿瘤复发与转移的灵敏度、特异性和准确性分别为98.1％(52/53)、95.2％ (40/42)和96.8％ (92/95),阳性预测值与阴性预测值分别为96.3％ (52/54)和97.6％(40/41).18F-FDG PET/CT检查结果与病理及临床随访结果一致性良好(Kappa=0.936,P＜0.05).结论 18F-FDG PET/CT对临床可疑宫颈癌复发的诊断具有较高的灵敏度和特异性,有助于局部复发和(或)远处转移病灶的检测,对临床进一步的诊疗具有指导作用.     

18F-FDG PET/CT在黑色素瘤中的应用价值

目的 探讨18F-脱氧葡萄糖(FDG)PET/CT显像在黑色素瘤诊断、临床分期及监测治疗后肿瘤复发与转移灶中的应用价值.方法 黑色素瘤患者61例,均进行18F-FDG PET/CT全身显像.所有PET、CT及PET/CT融合图像均通过融合软件进行帧对帧对比分析.肿瘤病灶根据病理学检查、多种影像学检查及临床随访结果诊断.结果 18F-FDG PET/CT显像对黑色素瘤病灶检出的灵敏度、特异性和准确性分别为90.9%(40/44)、88.2%(15/17)和90.2%(55/61).其中12例治疗前患者中,18F-FDG PET/CT显像诊断的灵敏度为83.3%(10/12).在黑色素瘤病灶局部切除、尚未进行其他治疗的9例患者中,5例残余病灶18F-FDG PET/CT显像检出3例;4例远处转移灶患者全被检出,提高了临床分期,改变了治疗方案.首先发现转移性黑色素瘤病灶并且手术切除后,寻找原发灶的7例患者中,18F-FDG PET/CT检出原发灶2例,4例其他转移灶全被检出.黑色素瘤患者根治术后监测肿瘤复发或转移患者33例,18F-FDG PET/CT显像灵敏度、特异性和准确性分别为100.0%(19/19)、85.7%(12/14)和93.9%(31/33).与同期临床其他影像学检查比较,18F-FDG PET/CT显像发现更多,33例患者中,16例(48.5%)病灶提高临床分期;7例(21.2%)排除可疑病灶,降低临床分期;10例(30.3%)检出病灶与临床一致.结论 18F-FDG PET/CT显像对于黑色素瘤的诊断,残余病灶、复发病灶及转移灶的检出,临床分期的明确具有重要价值.     

^18F—FDG PET显像与^99Tc^m—MDP全身骨显像诊断肿瘤远处转移的比较

目的 评价^18F-脱氧葡萄糖（FDG）PET肿瘤显像与^99Tc^m-亚甲基二膦酸盐（MDP）全身骨显像对检出骨和远处转移的价值。方法 对16例恶性肿瘤放化疗后的患者进行^18F-FDG PET显像和^99Tc^m-MDP全身骨显像，并对两种结果进行了比较。结果 16例肿瘤患者中^18F-FDG PET显像皆阳性，其中14例患者有远处转移，转移病灶共62处，其中骨转移病灶20处；在全身骨显像中，11例有局限性异常放射性浓聚，其中2例为单一病灶，9例为多发病灶，共检出病灶57处，另5例骨显像正常。结论 ^18F-FDG PET对恶性肿瘤的诊断具有较高的准确性和特异性，但对骨转移灶的诊断价值相对较差；^99Tc^m-MDP显像阴性或单一病灶的可疑转移瘤患者有必要进行^18F－FDG PET检查，以明确诊断其他远处转移灶。     

18F-FDG PET/CT对肾脏肿瘤的诊断价值

目的 探讨18F-FDG PET/CT对肾脏肿瘤的临床诊断价值.方法 回顾性分析近5年经18 F-FDG PET/CT诊断为肾脏肿瘤且病理或临床综合诊断明确的79例患者资料,其中男52例,女27例,平均年龄(57.3±14.1)岁.PET/CT诊断根据肾脏轮廓改变、病灶密度异常及FDG摄取程度做出.计算18F-FDG PET/CT诊断肾脏肿瘤的效能指标.结果 79例中恶性肿瘤70例(包括肾细胞癌40例、肾盂癌5例,淋巴瘤8例,转移瘤16例,肾筋膜囊脂肪肉瘤1例);良性肿瘤9例(包括血管平滑肌脂肪瘤7例,肾嗜酸细胞腺瘤1例,后肾腺瘤1例;不含小脂滴样错构瘤病例).18 F-FDG PET/CT对病灶检出率达97.5％(77/79),对肾脏良恶性病灶判断的灵敏度为92.9％ (65/70),特异性为7/9,准确性为91.1％ (72/79),阳性预测值为97.0％(65/67),阴性预测值为58.3％ (7/12).结论 18 F-FDG PET/CT能够检出并判断大部分肾脏占位病变性质,对肾脏肿瘤患者进行全身检查并做出综合评价是18F-FDG PET/CT的优势之一.     

~(18)F-FDGPET/CT显像在结直肠癌诊断中的应用价值

18F-FDGPET/CT是一种将CT解剖结构成像与PET功能代谢显像融合于一身的显像技术,能够在活体状态下对肿瘤组织进行定性和定位分析,在肿瘤显像领域发挥着重要作用,并且临床应用日益广泛。就18FFDG PET/CT显像原理,在结直肠癌术前诊断和术后复发中的应用(包括术后局部复发和术后远处转移的诊断),以及血清肿瘤标志物升高时18F-FDG PET/CT显像的诊断价值等予以综述。     

18F-FDG PET/CT显像在宫颈癌术后复发和转移中的应用价值

目的 探讨18F-FDG PET/CT显像在宫颈癌术后复发和转移中的应用价值.方法 搜集临床可疑宫颈癌术后复发和转移患者65例,年龄23～77岁,平均48.7岁.所有宫颈癌患者均经手术病理确诊并行根治性治疗,其中鳞癌47例,腺癌12例,腺鳞癌4例,透明细胞癌1例,小细胞癌1例.患者均行18F-FDG PET/CT全身显像检查,采用目测法和半定量法判断结果,并与组织病理或临床随访结果比较其诊断的准确性,以及评价其诊断的真实性和可靠性.结果 65例患者经组织病理或临床随访证实50例复发和转移.18F-FDG PET/CT显像诊断肿瘤局部复发18例,肿瘤转移33例,复发和转移病灶的SUVmax 2.91 ～ 16.70,平均SUVmax 9.81,18F-FDG PET/CT显像诊断宫颈癌术后复发和转移的灵敏度为98.00％,特异性为86.67％,准确性为95.38％,阳性预测值为96.08％,阴性预测值为92.86％;18F-FDG PET/CT显像诊断结果与组织病理或临床随访结果比较差异无统计学意义(经x2检验,P＞0.05);二者结果的吻合度有统计学意义且吻合度较强(系数k=0.867,P=0.000).结论 18F-FDG PET/CT显像能够准确、直观地显示宫颈癌术后复发和转移,且真实性和可靠性好;同时18F-FDG PET/CT全身显像检查是肿瘤远处转移探测最有效的方法,可较全面评估患者病情,对协助临床确定个体化治疗方案具有重要价值.     

18F-FDG PET/CT显像在胃癌分期及治疗方案制定中的应用价值

目的探讨18F-FDG PET/CT显像在胃癌分期及治疗方案制定中的应用价值。方法回顾性分析46例临床疑诊胃癌患者的18F-FDG PET/CT图像,采用目测法和半定量法对患者PET/CT图像进行分析,即测定SUV_max与最大胃壁厚度（T_max）,以胃镜或手术后取得的病理结果作为“金标准”,评估18F-FDG PET/CT显像对病灶的诊断效能,并采用Pearson相关分析法分析SUV_max与T_max的相关性。结果18F-FDG PET/CT诊断原发病灶的灵敏度、特异度和准确率分别为94.4%、40.0%和82.6%;原发灶SUV_max与T_max呈正相关（r=0.922,P=0.001）;18F-FDG PET/CT诊断淋巴结转移及远处转移的灵敏度、特异度和准确率分别为76.9%、90.0%、82.6%和92.9%、96.9%、95.7%。结论18F-FDG PET/CT在检测胃癌的原发病灶、淋巴结转移灶和远处转移灶时有较高的特异度和灵敏度,在评估临床分期、指导临床制定正确的治疗方案中具有重要的应用价值。     

18F-FDG PET/CT在宫颈癌诊断中的应用

目的 探讨18F-脱氧葡萄糖(FDG) PET/CT在宫颈癌诊断及其复发、转移灶探测中的应用价值.方法 88例患者行腹部或全身18F-FDG PET/CT显像,其中初诊者30例(宫颈良性病变11例,宫颈癌19例),宫颈癌治疗后58例.病灶根据病理检查、多种影像诊断技术及临床随访确诊,随访时间均为6个月～3年.结果 30例初诊者中,PET/CT诊断宫颈癌的灵敏度、特异性和准确性分别为17/19,10/11和27/30(90.0%).58例治疗后患者中,11例存在肿瘤复发或残余,PET/CT诊断肿瘤复发、残余的灵敏度、特异性和准确性分别为10/11,47/47(100.0%)和57/58(98.3%).41例有肿瘤转移,PET/CT诊断转移灶的灵敏度、特异性和准确性分别为92.7%,88.9%和90.9%;转移灶以盆腹腔淋巴结为主,39.0%有盆腔淋巴结转移,27.3%有腹膜后淋巴结转移,所有淋巴结转移患者中PET/CT发现26.8%病灶直径＜1.0cm.28.6%(22/77)的患者PET/CT发现腹腔外远处转移灶.18例输尿管梗阻患者中,16例PET/CT发现为肿瘤侵犯压迫所致.结论 18F-FDG PET/CT显像在宫颈癌的诊断及其复发、转移灶探测中有良好的应用价值,尤其是对远处转移灶和小淋巴结转移灶的检测,可使临床分期更准确.     

口腔鳞癌的18F-FDG PET/CT的影像学表现以及与CT平扫的比较研究

目的 评价18F-FDG PET-CT检查在口腔鳞癌患者的诊断和淋巴结转移灶发现的价值.方法 回顾性地分析了18例口腔癌(其中包括16例舌癌和2例口底癌患者)的临床和18F-FDG PET-CT影像学表现及CT平扫的影像学资料.结果 (1)原发病灶的发现全部病例中有5例患者是由PET/CT检查首次发现口腔癌的;PET/CT对原发部位肿瘤病变显示的灵敏度100%(15/15),特异性100%(3/3);CT对原发病灶显示的灵敏度为73.3%(11/15),特异性为66.7%(2/3).(2)18例口腔癌患者中PET/CT诊断颈部淋巴结转移灶共26个,大小介于0.8～1.5 cm之间,标准摄取值(SUV)介于2.5～3.2之间;其中仅有5个淋巴结经病理组织活检证实为淋巴结转移灶.(3)通过PET/CT检查新发现全身其他部位的侵犯和远处转移性病灶8个.结论 PET/CT对口腔鳞癌原发灶诊断的灵敏度和特异性均比CT平扫高;全身PET/CT扫描对舌癌和口底癌的临床分期、术后复发的判定更具价值.     

胃腺癌乳腺转移18F-FDG PET/CT显像一例

笔者报道了1例胃腺癌乳腺转移18F-氟脱氧葡萄糖（FDG）PET/CT显像的病例,从临床表现、18F-FDG PET/CT影像学表现、病理诊断及鉴别诊断等方面分析了该病的特点。胃腺癌乳腺转移在临床上罕见,临床表现缺乏特异性,易漏诊及误诊,确诊需经组织病理学检查。18F-FDG PET/CT检查可以早期筛查全身病灶,提高诊断的准确率。     

Breast cancer staging in a single session: whole-body PET/CT mammography

Our objective was to compare the diagnostic accuracy of an all-in-one protocol of whole-body 18F-FDG PET/CT and integrated 18F-FDG PET/CT mammography with the diagnostic accuracy of a multimodality algorithm for initial breast cancer staging. METHODS: Forty women (mean age, 58.3 y; range, 30.8-78.4 y; SD, 12 y) with suspected breast cancer were included. For the primary tumor, we compared 18F-FDG PET/CT mammography versus MRI mammography; for axillary lymph node status, 18F-FDG PET/CT versus clinical investigation and ultrasound; and for distant metastases, 18F-FDG PET/CT versus a multimodality staging algorithm. Histopathology and clinical follow-up served as the standard of reference. The Fisher exact test evaluated the significance of differences (P < 0.05). Alterations in patient management caused by 18F-FDG PET/CT were documented. RESULTS: No significant differences were found in the detection rate of breast cancer lesions (18F-FDG PET/CT, 95%; MRI, 100%; P = 1). 18F-FDG PET/CT correctly classified lesion focality significantly more often than did MRI (18F-FDG PET/CT, 79%; MRI, 73%; P < 0.001). MRI correctly defined the T stage significantly more often than did 18F-FDG PET/CT (MRI, 77%; 18F-FDG PET/CT, 54%; P = 0.001). 18F-FDG PET/CT detected axillary lymph node metastases in 80% of cases; clinical investigation/ultrasound, in 70%. This difference was not statistically significant (P = 0.067). Distant metastases were detected with 18F-FDG PET/CT in 100% of cases, and the multimodality algorithm identified distant metastases in 70%. This difference was not statistically significant (P = 1). Three patients had extraaxillary lymph node metastases that were detected only by PET/CT (cervical, retroperitoneal, mediastinal/internal mammary group). 18F-FDG PET/CT changed patient management in 12.5% of cases. CONCLUSION: Our data suggest that a whole-body 18F-FDG PET/CT mammography protocol may be used for staging breast cancer in a single session. This initial assessment of the 18F-FDG PET/CT protocol indicates similar accuracy to MRI for the detection of breast cancer lesions. Although MRI seems to be more accurate when assessing the T stage of the tumor, 18F-FDG PET/CT seems able to more accurately define lesion focality. Although 18F-FDG PET/CT mammography was able to detect axillary lymph node metastases with a high sensitivity, this method cannot soon be expected to replace the combination of clinical examination, ultrasound, and sentinel lymph node biopsy for axillary assessment.     

18F-FDG PET/CT for staging of penile cancer.

The value of PET or PET/CT with (18)F-FDG for the staging of penile cancer has yet to be determined. The objective of this study was to investigate the pattern of (18)F-FDG uptake in the primary malignancy and its metastases and to determine the diagnostic value of (18)F-FDG PET/CT in the staging and restaging of penile cancer. METHODS: Thirteen patients (mean +/- SD age, 64 +/- 14.0 y) with suspected penile cancer or suspected recurrent disease were examined with a Gemini PET/CT system (200 MBq of (18)F-FDG). The reference standard was based on histopathologic findings obtained at biopsy or during surgery. RESULTS: Both the primary tumor and regional lymph node metastases exhibited a pattern of (18)F-FDG uptake typical for malignancy. Sensitivity in the detection of primary lesions was 75% (6/8), and specificity was 75% (3/4). On a per-patient basis, sensitivity in the detection of lymph node metastases was 80% (4/5), and specificity was 100% (8/8). On a nodal-group basis, PET/CT showed a sensitivity of 89% (8/9) in the detection of metastases in the superficial inguinal lymph node basins and a sensitivity of 100% (7/7) in the deep inguinal and obturator lymph node basins. The mean +/- SD maximum standardized uptake value for the 8 primary lesions was 5.3 +/- 3.7, and that for the 16 lymph node metastases was 4.6 +/- 2.0. CONCLUSION: According to our results, the main indication for (18)F-FDG PET in the primary staging or follow-up of penile cancer patients may be the prognostically crucial search for lymph node metastases. With the use of a PET/CT unit, the additional information provided by CT may be especially useful for planning surgery. Implementing (18)F-FDG PET and PET/CT in future staging algorithms may lead to a more precise and stage-appropriate therapeutic strategy. Furthermore, invasive procedures with a high morbidity rate, such as general bilateral lymphadenectomy, may be avoided.     

^18F-FDG PET／CT在胰腺癌诊断中的价值

目的评价^18F-脱氧葡萄糖（FDG）PET／CT鉴别诊断胰腺良恶性病变及检测淋巴结和（或）远处转移的价值。方法回顾性分析上海交通大学医学院附属仁济医院行^18F—FDGPET／CT检查的46例临床疑胰腺肿瘤患者的影像学检查资料和临床资料,其中胰腺癌患者26例,良性病变者20例,比较分析PET和CT的特征。结果当选择最大标准摄取值（SUVmax）=2．95为判断良恶性的界值时,对胰腺癌诊断的灵敏度是88．5％（23／26）,特异性是85．0％（17／20）。^18F—FDGPET／CT显像假阳性3例,假阴性3例。同时发现16例检查前未确定的肝、肺、骨及淋巴结转移患者。根据显像结果,11例患者治疗方案得以修正。结论根据现有资料分析,^18F—FDGPET／CT是鉴别诊断胰腺良恶性病变及检测胰腺癌患者淋巴结和（或）远处转移一种较好的方法。     

A case of renal pelvic tumor visualized by<Superscript>18</Superscript>F-FDG-PET imaging

18F fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging is a useful modality in detecting various tumors, including renal cell carcinoma. We evaluated a patient with renal pelvic tumor (transitional cell carcinoma) with multiple metastases using 18F-FDG PET imaging and detected abnormal increased uptake of a right renal pelvic tumor extending to the renal cortex with liver metastasis and paraaortic lymph node metastases. These results suggest that 18F-FDG PET imaging may be useful in detecting primary and metastatic lesions of renal pelvic tumor (transitional cell carcinoma).     

Clinical utility of 18F-FDG PET for patients with salivary gland malignancies.

The clinical utility of 18F-FDG PET in evaluating salivary gland malignancies has not been well defined. We therefore evaluated the utility of 18F-FDG PET in management for patients with salivary gland cancers. METHODS: Thirty-four patients with newly diagnosed salivary gland cancers underwent CT and 18F-FDG PET before surgical resection with radiotherapy. The diagnostic accuracies of CT and 18F-FDG PET for detecting primary tumors and neck metastases were compared with a histopathologic reference. We determined the relationship between the maximum standardized uptake value (SUV) of the tumor and clinicopathologic parameters such as sex, age, local tumor invasion, T and N categories, TNM stage, and histologic grade, as well as their associations with disease-free survival (DFS). RESULTS: 18F-FDG PET was more sensitive than CT for the detection of primary tumors (91.2% vs. 79.4%; P < 0.05), cervical metastases (80.5% vs. 56.1%; P < 0.05), and distant metastases in 2 patients at initial staging. High-grade malignancies had higher mean maximum SUVs than did low- and intermediate-grade malignancies (4.6 vs. 2.8; P = 0.011). T and N categories were independent determinants of DFS (P < 0.05), but the maximum SUV (4.0) was not. During a mean follow-up of 25.1 mo, 18F-FDG PET correctly diagnosed local-regional recurrences in 6 patients and new distant metastases in 9 patients. CONCLUSION: Our findings indicate that, in patients with salivary gland malignancies, 18F-FDG PET is clinically useful in initial staging, histologic grading, and monitoring after treatment but not in predicting patient survival.     

Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors

As fluorine-18-fluorodesoxyglucose positron emission tomography/computed tomography ( (18)F-FDG PET/CT) is gaining wider availability, more and more patients with malignancies undergo whole body PET/CT, mostly to assess tumor spread in the rest of the body, but not in the brain. Brain is a common site of metastatic spread in patients with solid extracranial tumors. Gold standard in the diagnosis of brain metastases remains magnetic resonance imaging (MRI). However MRI is not routinely indicated and is not available for all cancer patients. Fluorine-18-FDG PET is considered as having poor sensitivity in detecting brain metastases, but this may not be true for PET/CT. The aim of our study was to assess the value of (18)F-FDG PET/CT in the detection of brain metastases found by whole body scan including the brain, in patients with solid extracranial neoplasms. A total of 2502 patients with solid extracranial neoplasms were studied. All patients underwent a routine whole body (18)F-FDG PET/CT scan with the whole brain included in the scanned field. Patients with known or suspected brain metastases were preliminary excluded from the study. Hypermetabolic and ring-like brain lesions on the PET scan were considered as metastases. Lesions with CT characteristics of brain metastases were regarded as such irrespective of their metabolic pattern. Lesions in doubt were verified by MRI during first testing or on follow-up or by operation. Our results showed that brain lesions, indicative of and verified to be metastases were detected in 25 out of the 2502 patients (1%), with lung cancer being the most common primary. Twenty three out of these 25 patients had no neurological symptoms by the time of the scan. The detection rate of brain metastases was relatively low, but information was obtained with a minimum increase of radiation burden. In conclusion, whole body (18)F-FDG PET/CT detected brain metastases in 1% of the patients if brain was included in the scanned field. Brain scanning as a part of whole body scan cannot replace routine imaging techniques, but in case of positive findings provides early and crucial information for further patient management, especially in asymptomatic patients.     

18F-FDG PET/CT在原发灶不明的脑转移瘤中的诊断价值

目的 探讨18F-FDG PET/CT在查找原发灶不明的脑转移瘤中的价值。 方法 回顾性分析17例原发灶不明的脑转移瘤患者的全身18F-FDG PET/CT检查资料。 结果 17例患者均经活检确诊原发灶,准确率100%。原发性肺癌13例,占76%,其中有2例在第二次行PET/CT检查时才检出原发灶;原发性肝癌2例,占12%;原发性贲门癌1例,占6%;原发性升结肠癌1例,占6%。在检查到原发灶的基础上,18F-FDG PET/CT亦发现10例合并转移者,其中合并肺转移者2例、合并淋巴结转移者3例、合并骨转移者2例及合并其他部位转移者3例,共发现病灶61处;2例肝癌患者单发脑转移灶中均有脑卒中。 结论 18F-FDG PET/CT在查找原发灶不明的脑转移瘤原发灶中有重要价值,并为临床分期及治疗提供有利帮助。     

^18F-FDG PET／CT在诊断转移性肝肿瘤中的应用

目的：探讨^18F-FDG PEF／CT在诊断转移性肝肿瘤中的应用。方法：回顾性分析49例转移性肝肿瘤患者的PET／CT影像资料,探讨^18F-FDG PET／CT诊断转移性肝肿瘤的影像表现及应用价值。结果：49例转移性肝肿瘤患者中45例^18F-FDG PET／CT表现为病灶^18F-FDG摄取明显高于周围正常肝组织;其中25例进行了延迟显像,22例表现为SUVmax及T／N值明显升高;发现肝转移同时伴有肝外转移患者38例。结论：^18F-FDG PET／CT诊断转移性肝肿瘤灵敏度高,准确,并可以同时对全身情况加以评价,对肿瘤患者肝转移的评价及治疗具有重要指导作用。     

Opportunities for 2-[18F] Fluoro-2-Deoxy-D-Glucose PET/CT in Cervical-Vaginal Neuroendocrine Carcinoma: Case Series and Literature Review

Objective

Neuroendocrine cervical carcinoma is a rare subtype of cervical cancer. These tumors exhibit an aggressive behavior with early regional lymph node and distant metastases. The purpose of our study was to describe five cases of neuroendocrine cervical-vaginal carcinoma and to discuss the potential of the 2-[¹⁸F] fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) scan for the detection of this rare malignancy.

Materials and Methods

Five cases of cervical-vaginal neuroendocrine tumor were retrospectively collected, during a two year (from September 2009 to August 2011) period in our hospital. The clinical staging distributions were International Federation of Gynecology and Obstetrics (FIGO) stage IB2 (1 of 5), stage IIA (3 of 5) and stage IVA (1 of 5).

Results

Two cases (cases 1 and 4) were restaged after ¹⁸F-FDG PET/CT scan in the initial staging process. Post-treatment ¹⁸F-FDG PET/CT scans, in three patients, revealed positive findings for tumor recurrence or lymph node metastases. Two patients (cases 2 and 3) died of tumor within two years.

Conclusion

¹⁸F-FDG PET/CT scan is a useful tool in cervical-vaginal neuroendocrine tumor. In its initial staging, the ¹⁸F-FDG PET/CT scan may help assess the possible nodal involvement or early hematogeneous spreading. We can also use the ¹⁸F-FDG PET/CT to detect local recurrence and to evaluate the treatment response after clinical manipulation.     

^18F-FDG PET/CT对可疑复发性宫颈癌的临床价值

目的 探讨^18F-FDG PET/CT在可疑复发性宫颈癌临床诊疗中的价值.方法 回顾性分析51例宫颈癌根治后随访期间临床可疑复发的患者,记录患者的治疗资料、可疑复发表现、18F-FDG PET/CT显像结果、同期常规影像检查结果、病理及临床随访结果、PET/CT结果对临床诊疗的影响.结果 PET/CT诊断宫颈癌复发43例,最终经病理检查及临床随访证实复发性宫颈癌40例,盆腔脓肿2例,放射性肠炎1例;PET/CT未见恶性征象8例,病理检查及临床随访均未见异常.PET/CT诊断复发性宫颈癌灵敏度为100.00%（40/40）,特异性为72.73%（8/11）,准确性为94.12%（48/51）.PET/CT指导制订临床诊疗及随访计划34例,改变治疗计划7例.与其他影像检查相比,PET/CT可发现更多的病灶.结论^18F-FDG PET/CT能有效诊断复发性宫颈癌,指导临床诊疗.